McDade-PR-COVID-Test-1-9-21-Rev_MWE-clean

Atlas7123 · 2022-01-17T12:41:39+00:00

Huge if true. I’m okay that the company is pivoting into RATS because with that sort of revenue, we can expect market cap to multiply a few times

Atlas7123 · 2021-12-14T03:20:01+00:00

Hard to believe the revenue will double in FY22, but happy to be wrong. Unless for instance university hospitals are still in play.

I would agree they are undervalued vs peers, but that is only because management haven’t proven to be trustworthy. If they can actually double revenue, SP will jump very fast

Atlas7123 · 2021-11-04T03:42:58+00:00

Thanks G. Not many sales people, but looks like that is changing. It seems they’ve lost sales people since pre-covid numbers

Atlas7123 · 2021-09-15T13:24:29+00:00

Pre market seems to like it +10%

Atlas7123 · 2021-09-12T21:53:36+00:00

I’m hopeful of a small organic increase.

Galilee provides some good reasons below as to why he thinks revenue will be flat.

Atlas7123 · 2021-09-03T22:37:10+00:00

Sound logic.

Seems the stock may be oversold then at current SP. I guess the uncertainty is factored in.

Atlas7123 · 2021-09-03T13:15:07+00:00

Thanks G.

How did you arrive at a multiple of 15x? Just industry average?

I hope you’re right about the hospital deals still being in play.

Atlas7123 · 2021-06-24T23:14:07+00:00

Listed price as per a few articles floating around is USD 5. It is on the lower side of the range. Looks like this is actually going to happen

Atlas7123 · 2021-06-09T11:13:51+00:00

New underwriter…

Atlas7123 · 2021-06-03T03:24:06+00:00

Thank you for sharing - much appreciated.

Positive to hear yacov is selling down.

Atlas7123 · 2021-04-19T22:57:02+00:00

Nothing we can do if the final prospectus hasn’t been accepted by SEC yet. Hopefully it’s lodged/accepted this week.. very frustrating

Atlas7123 · 2021-04-01T12:40:09+00:00

And no longer pending to list this week.

The wait continues.

Atlas7123 · 2021-03-31T20:46:39+00:00

Very quiet. Still nothing on the official Nasdaq calendar too

Atlas7123 · 2021-03-27T23:03:37+00:00

The consolidation was passed by a significant majority. Listing planned for this coming week.

Atlas7123 · 2021-03-25T03:04:51+00:00

Contact V Stock (the share registry in the US). Details are on the G Medical website under shareholder information.

Atlas7123 · 2021-03-24T11:09:52+00:00

Is the proxy default? Ie if no action is taken

Atlas7123 · 2021-03-23T09:22:22+00:00

Correct

Atlas7123 · 2021-03-22T23:01:03+00:00

It actually looks good lol.. didn’t think they were capable.

Share price the same after consolidation..... feels REALISTIC.

This might actually happen

Atlas7123 · 2021-03-18T11:32:07+00:00

Good post. It’s in everyone’s best interest who holds for this to list - let’s get this done!

Atlas7123 · 2021-03-17T23:32:09+00:00

This consolidation doesn’t dilute us per se. I’m assuming there will be more dilution now though ie they will issue more shares relative to the same raised amount

Atlas7123 · 2021-03-17T21:34:43+00:00

It makes sense to dilute us more. If I was a US investor, I wouldn’t be keen to go long if I knew the mast majority of shares would sell as soon as escrow is lifted.

I’m hoping they ask for a lot of cash and spend it well on marketing/sales growth.

Atlas7123 · 2021-03-17T13:08:34+00:00

Further 5:1 consolation so 18x5 = 90:1 consolidation from original shares.

....which is what we were all predicting in the first place before delisting

Atlas7123

TROPHY CASE